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Abstract
 
The Notch ligand, Jagged-1, plays an essential role in tissue formation during embryonic de-
velopment of primitive organisms. However, little is known regarding the role of Jagged-1 in
the regulation of tissue-specific stem cells or its function in humans. Here, we show that un-
committed human hematopoietic cells and cells that comprise the putative blood stem cell mi-
croenvironment express Jagged-1 and the Notch receptors. Addition of a soluble form of hu-
man Jagged-1 to cultures of purified primitive human blood cells had modest effects in
augmenting cytokine-induced proliferation of progenitors. However, intravenous transplanta-
tion of cultured cells into immunodeficient mice revealed that human (h)Jagged-1 induces the
survival and expansion of human stem cells capable of pluripotent repopulating capacity. Our
findings demonstrate that hJagged-1 represents a novel growth factor of human stem cells,
thereby providing an opportunity for the clinical utility of Notch ligands in the expansion of
primitive cells capable of hematopoietic reconstitution.
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Introduction
 
The evolutionarily conserved Notch signaling pathway has
been shown to play a critical role in the development and
patterning of a wide variety of organisms including worms,
flies, and mice (1). Instructive Notch signals are mediated by
cell–cell interactions between Notch receptor and Notch
ligands that control cell fate decisions. Although the definite
relationship between Notch signaling and biological out-
come is dependent on the specific cell type, growth factor
environment, and species, it is clear that Notch activation is
capable of inhibiting differentiation and progression of pre-
cursor populations to more developmentally restricted cells
(2, 3). In addition to pluripotency, many of these precursors
are capable of immense proliferative capacity, suggesting
that Notch activation may be intricately related to the con-
trol of differentiation and proliferation of stem cells (4). Al-
though fundamental influences of Notch signaling in devel-
opmental processes may be pertinent to medical applications
(5), the specific role of ligand-induced Notch activation in
primary human stem cells is currently unknown.
Notch receptors interact with a family of transmembrane
proteins that serve as ligands containing a highly conserved
Delta-Serrate-Lag-2 (DSL) domain in the extracellular re-
gion. Activation of Notch signaling is mediated through
interactions between the DSL domain and specific epider-
mal growth factor (EGF) repeats located in the extracellular
portion of the Notch receptor (6). The Drosophila Notch
ligand, Serrate, is a family member of Notch ligands cloned
from invertebrates (7, 8). Jagged-1, the mammalian homo-
 
logue of Serrate, has been shown to be a potent activator
of the Notch signaling pathway in a variety of cell types,
mediating signals via cellular interactions with adjacent
Notch-expressing cells (9). Here, using hematopoietic de-
velopment as a well characterized model system for primary
human cells, we investigated the potential role of Jagged-
1–induced Notch signaling in humans (10).
Ex vivo culture conditions originally optimized using
surrogate in vivo models to detect human hematopoietic
stem cell function in immunodeficient recipients have re-
cently led to enhanced hematopoietic reconstitution and
 
Address correspondence to Mickie Bhatia, The John P. Robarts Research
Institute, Developmental Stem Cell Biology, 100 Perth Dr., London,
Ontario, Canada N6A 5K8. Phone: 519-663-5777 Ext. 34166; Fax: 519-
663-3789; E-mail: mbhatia@rri.on.ca 
1366
 
Jagged-1 Regulates Human Blood Stem Cells
 
retroviral gene transfer of repopulating stem cells in clinical
trials (11, 12). However, although these ex vivo culture
conditions provide a therapeutic benefit, the magnitude of
the expansion and gene transfer efficiency is insufficient for
the treatment of a wider variety of patient pathologies.
Therefore, the success of ex vivo expansion conditions still
awaits the identification of factors capable of inducing pro-
liferation of rare stem cells. In this study, production of a
soluble form of human (h)Jagged-1 provided a means to
functionally evaluate the role of hJagged-1 in ex vivo cul-
tures of highly purified human hematopoietic cells. Al-
though addition of hJagged-1 had modest effects in
enhancing cytokine-induced proliferation of primitive pro-
genitors detected in vitro, intravenous transplantation of
cultured cells into immunodeficient nonobese diabetic
(NOD)/SCID mice revealed that hJagged-1 is capable of
maintaining the survival and expanding human stem cells
capable of pluripotent reconstituting capacity. Unlike he-
matopoietic cytokines, this unique function of hJagged-1
provides an opportunity for the optimization for clinical
protocols aimed at ex vivo expansion and gene transfer of
human stem cells.
 
Materials and Methods
 
Expression of Human Notch 1 and 2 and Jagged-1.
 
Reverse
transcription (RT)-PCR reactions were performed on cDNA
using primer sequences as follows: Notch 1, forward 5
 
9
 
-GATG-
CCAACATCCAGGACAACATGGG-3
 
9 
 
and reverse 5
 
9
 
-GGC-
AGGCGGTCCATATGATCCGTGAT-3
 
9
 
; Notch 2, forward
5
 
9
 
-ACATCATCACAGACTTGGTC-3
 
9
 
 and reverse 5
 
9
 
-CATT-
ATTGACAGCAGCTGCC-3
 
9
 
; and Jagged-1, forward 5
 
9
 
-GAT-
CCTGTCCATGCAGAACG-3
 
9
 
 and reverse 5
 
9
 
-GGATCTG-
ATACTCAAAGTGG-3
 
9
 
. PCR products were sequenced to
verify specificity of amplified DNA.
 
Preparation of hJagged-1 Protein.
 
hJagged-1 cDNA was isolated
by plaque hybridization from human placenta and fetal brain
cDNA libraries (CLONTECH Laboratories, Inc.). Sequences
were determined and verified using an ABI DNA sequencer
(model 375S; PerkinElmer). Partial cDNA encoding the entire
extracellular domain of Jagged-1 was fused in frame to a sequence
of human IgG
 
1
 
 or FLAG octapeptide. Jagged-1 gene fusions were
inserted into the expression vector pcDNA3 (Invitrogen) or pM-
KITneo (provided by Dr. K. Maruyama, Tokyo Medical and
Dental University, Tokyo, Japan) and electroporated into Chi-
nese hamster ovary cells with subsequent G418 selection. Expres-
sion of soluble Jagged-1 protein was verified with anti–human
IgG
 
1
 
 (Amersham Pharmacia Biotech) or anti-FLAG (M2; East-
man Kodak Co.) antibody. Both human IgG
 
1
 
 and FLAG chimera
proteins were purified from conditioned media by affinity chro-
matography according to methods previously described (13).
 
Cell Purification.
 
Human cord blood (CB) mononuclear cells
were isolated and enriched for primitive uncommitted cells (lin-
eage [Lin]
 
2
 
) with CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 cell populations subse-
quently isolated by sorting, as previously described (14). Mature
populations of myeloid, T, and B cells were isolated using hu-
man-specific CD33, CD3, and CD19, respectively.
 
Treatment of Cells with hJagged-1.
 
Purified CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 CB cells were cultured in serum-free media containing cy-
tokines designed to sustain human repopulating stem cells, as pre-
viously described (14). Cells were incubated for indicated periods
 
at 37
 
8
 
C and 5% CO
 
2
 
 in the presence of IgG
 
1
 
 (control treated) or
10 
 
m
 
g/ml hJagged-1–IgG
 
1
 
. Recombinant IgG
 
1
 
 proteins were
added to cultures treated with cytokine cocktail alone, in the ab-
sence of hJagged-1, to control for nonspecific effects of IgG
 
1
 
 pro-
tein. Recombinant IgG
 
1
 
 proteins had no effect compared with
hematopoietic cytokine cocktail alone. Shorter term cultures ana-
lyzed at 4–12 d were done independently of cultures analyzed at
15–25 d.
 
Clonogenic Progenitor Assays.
 
Human clonogenic progenitor
assays were performed by plating equal numbers of Jagged-1 or
control treated cells using previously defined conditions (14) and
scoring after 10–14 d.
 
Transplantation and Analysis of NOD/SCID Mice.
 
Cultured
cells were transplanted via tail vein injection into irradiated
NOD/SCID mice according to standard protocols along with
100,000 irradiated CD34
 
2
 
Lin
 
1
 
 cells (14). Mice were killed 6–8
wk after transplantation, and murine bone marrow (BM) cells
were collected for analysis. Genomic DNA was extracted from
the BM cells of transplanted mice and 1–2 
 
m
 
g of DNA that was
EcoRI digested and probed using a human-specific chromosome
17 
 
a 
 
satellite probe (p17H8) as shown previously (14). Quantita-
tion was performed by comparison to standards of known murine
and human DNA mixtures. In addition, BM cells were stained
with fluorochrome-conjugated antibodies specific to human
CD45 (a pan leukocyte marker) and CD38 (Becton Dickinson)
and analyzed by flow cytometry using a FACSCalibur™ and
CELLQuest™ software (Becton Dickinson). Multilineage analy-
ses of BM cells from engrafted animals were gated to analyze hu-
man cells only in combination with either CD20–FITC and
CD19–PE, CD33–FITC (Becton Dickinson) and CD15–PE
(Immunotech), or CD34–FITC and CD38–PE (Becton Dickin-
son) mAbs. 
 
Results
 
Expression of hJagged-1 and Notch Receptors among Human
Hematopoietic Cells and Their Microenvironment.
 
Using in
vitro assays in mouse or human cell lines, investigators have
suggested that Notch signals may influence the growth of
hematopoietic progenitors detected in vitro (15–17). In ad-
dition, a bulk population of primitive CD34
 
1
 
 human
blood cells isolated from adult BM have been shown to ex-
press the Notch 1 receptor (18) and have been thought to
respond to Notch signal activation via interactions with
ligands expressed by adjacent cells. Adult stromal or human
umbilical vein endothelial cells (HUVECs) constitute the
microenvironment of hematopoietic stem cells found in
BM and CB, respectively. Here, primary BM stromal cells
and HUVECs were shown to express hNotch 1 and
hNotch 2 receptors in addition to Jagged-1, indicating that
these cells are capable of both responding to and eliciting
Notch signaling (Fig. 1 A). To further investigate the inter-
play between Notch and Jagged-1 in human hematopoietic
cells, primary human hematopoietic tissue from full gesta-
tional age CB was fractionated by cytometric cell sort-
ing into subsets of various lineages representing myeloid
(CD33
 
1
 
), T (CD3
 
1
 
), and B (CD19
 
1
 
) lymphoid cells using
lineage-specific markers (19). In addition, extremely rare,
primitive cells (
 
,
 
0.05% of mononuclear blood cells) de-
pleted of lineage-restricted cells (Lin
 
2
 
) expressing the stem
cell marker CD34 were separated into CD34
 
1
 
CD38
 
1
 
Lin
 
2 
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or candidate human hematopoietic CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
stem cell subfractions (19, 20). The level of purification of
these subsets was verified by FACS
 
®
 
 reanalysis and demon-
strated 
 
.
 
97% purity (Fig. 1 B). Notch 1 and Notch 2 re-
ceptors were shown to be expressed throughout human
hematopoietic maturation, indicating that human blood
cells are capable of responding to Notch ligands (Fig. 1 C).
Surprisingly, the Notch ligand Jagged-1 was also expressed
by both primitive and mature human hematopoietic cells
(Fig. 1 C). Therefore, in addition to responding to Notch-
activating signals from cognate stromal or endothelial mi-
croenvironments, primitive human blood cells expressing
Jagged-1 may be capable of inducing Notch signaling
among surrounding cells. Our data reveals that Notch re-
ceptor and ligand interactions within the human hemato-
poietic system are more complex than previously appre-
ciated (21) and may not only be restricted to Notch
activation of hematopoietic cells by stromal environments
but may include signaling among mature and primitive he-
matopoietic cells alike.
 
Soluble hJagged-1 Is Capable of Specific Interaction with Prim-
itive Human Hematopoietic Cells.
 
Based on our expression
studies, we sought to further define the functional role of
Jagged-1 in human hematopoietic stem cells using a soluble
form of hJagged-1. hJagged-1 cDNA was expressed in
transfected producer cell lines as a chimeric protein of ei-
ther human IgG
 
1
 
 or FLAG protein sequences and purified
from supernatants by affinity chromatography (13). Purified
soluble hJagged-1 was separated on SDS-PAGE and visual-
ized by Coomassie blue staining (Fig. 2 A, i). Purity and in-
tegrity of soluble hJagged-1 was verified by Western blot-
ting using anti–human IgG
 
1
 
 or anti-FLAG antibodies (Fig.
2 A, ii); a single protein product of the expected molecular
size was produced. In addition, purified Jagged-1 protein
product was shown to bind specifically to the Notch recep-
tor overexpressed in transfected COS cell lines (data not
shown).
To determine whether primary human uncommitted
hematopoietic cells (Lin
 
2
 
) were capable of binding soluble
Jagged-1, human Lin
 
2
 
 cell fractions were treated with
hJagged-1–FLAG protein followed by a complex of mouse
anti-FLAG fluorochrome-conjugated secondary antibody
and analyzed by flow cytometry. hJagged-1 was shown to
bind to primitive human hematopoietic cells (Fig. 2 B).
Specificity of hJagged-1 binding was demonstrated by
competing hJagged-1–FLAG cellular interaction by pre-
Figure 1. Expression of genes required for Notch signaling in
purified human hematopoietic cells and their microenvironment.
RT-PCR reactions were performed on cells using primers de-
signed from known sequences available from the database. RT-
PCR was performed on human fetal cDNA as a positive control
while a housekeeping gene expressed at a single copy per cell,
b-glucuronidase, was used to assess the quality and integrity of
cDNA templates generated. (A) hNotch-1, hNotch-2, and
hJagged-1 expression by cells of the hematopoietic environment
of adult BM stroma and HUVECs. (B) Mature CD331 myeloid
cells, CD31 T cells, CD191 B cells, and primitive subfractions of
CD341CD381Lin2 and CD341CD382Lin2 cells were isolated
by flow cytometric sorting and reanalyzed to verify level of puri-
fication. Re-analysis revealed a .97% purity for all subfractions.
(C) Expression of Notch signaling molecules hNotch-1,
hNotch-2, and hJagged-1 in purified primitive Lin2 cell subsets
and mature cells from multiple lineages (CD331 for myeloid,
CD31 for T cells, and CD191 for B cells). PCR products were
sequenced to verify specificity of gene amplification. 
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treating cells with hJagged-1–IgG
 
1
 
 (Fig. 2 B) or fully abol-
ishing hJagged-1–FLAG binding capacity with the addition
of 10 mM EDTA, which prevents Ca
 
2
 
1
 
-mediated Jagged–
Notch interactions of DSL–EGF domains (22) (Fig. 2 B).
EDTA or hJagged-1–IgG
 
1
 
 pretreatment had no effect on
the binding efficiency of other cell surface–targeted, fluo-
rochrome-conjugated antibodies detected by flow cytome-
try such as human CD34 (data not shown). Our results
illustrate that primitive human hematopoietic cells express-
ing the Notch receptor are capable of Jagged-1 ligand in-
teractions, thus providing a novel system in which to inves-
tigate the biological outcome of Jagged-1–induced Notch
signaling in humans.
 
hJagged-1 Induces Proliferation of Human Hematopoietic Pro-
genitors.
 
To characterize the role of Jagged-1 in human
blood formation and development, highly purified
CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 human stem cells (purity 
 
.
 
98%, Fig. 1
B) were isolated and cultured in optimized serum-free con-
ditions (23–25). Cells cultured with hematopoietic cyto-
kines were compared with those treated with soluble
hJagged-1. Recombinant IgG
 
1
 
 protein was added to cul-
tures treated with cytokine cocktail alone in the absence of
hJagged-1 (control treated) to control for nonspecific ef-
fects of IgG
 
1
 
. Addition of recombinant IgG
 
1
 
 protein at
equivalent concentrations had no effect when compared
conditions with hematopoietic cytokines cocktail alone.
Cultures were harvested at indicated times and examined
for changes in total cell proliferation, expansion of primi-
tive CD34
 
1
 
CD38
 
2
 
 subsets, and multilineage progenitor
function detected in vitro (Fig. 3). hJagged-1 treatment (10
 
m
 
g/ml) was able to expand the total number of cells in
short term cultures after 9 d. However, this modest effect
was lost after prolonged long term cultures beyond 15 d
(Fig. 3 A). Although hJagged-1 had little effect on the bulk
culture of cells, hJagged-1 was able to demonstrate more
noticeable expansion of total number of more primitive
CD34
 
1
 
CD38
 
2 
 
subsets in the culture between 9 and 25 d,
as compared with control treated cultures in the absence of
hJagged-1 (Fig. 3 B). In addition, the frequency of
CD34
 
1
 
CD38
 
2 
 
cells in Jagged-1 treated cultures was con-
sistently higher throughout all periods of culture as com-
 
pared with cultures treated with hematopoietic cytokines
alone (Fig. 3 B). The expansion of the CD34
 
1
 
CD38
 
2
 
 sub-
sets (and total CD34
 
1
 
 cells; data not shown) in response to
Jagged-1 suggests that Jagged-1 is capable of modestly
modulating phenotypically primitive human blood cells. In
addition to proliferative and phenotypic analysis, functional
assays for hematopoietic progenitors was performed after
4–25 d of hJagged-1 treatment and compared with control
treated cultures (Fig. 3 C). Although hJagged-1 treatment
did not increase clonogenic progenitors during early peri-
ods of ex vivo culture (
 
,
 
6 d), cells exposed to hJagged-1
for extended periods enhanced the expansion of progeni-
tors of multiple myeloid lineages (Fig. 3 C). Treatment
with hJagged-1 did not affect the developmental program
of progenitors, as the composition of lineage-restricted
progenitors (CFU type) did not differ between Jagged-1–
treated and control treated cultures (data not shown).
Taken together, our analysis of primary human blood cells
treated with hJagged-1 illustrates that Jagged-1 enhances
cytokine-induced proliferation of rare primitive subsets of
human hematopoietic cells without altering lineage devel-
opment.
 
hJagged-1 Represents a Hematopoietic Growth Factor Capable
of Expanding Pluripotent Human Repopulating Cells.
 
The
response of primitive human blood cells to Jagged-1 in
vitro suggests that Jagged-1 may play a role in modulating
rarer pluripotent hematopoietic stem cells capable of re-
population. To explore the potential effects of Jagged-1 in
regulating primitive human repopulating cells, purified cells
cultured with or without hJagged-1 were transplanted into
immunodeficient NOD/SCID mice (24, 26, 27). To
quantitatively determine the role of hJagged-1 on the num-
ber of human blood stem cells, individual wells were
seeded with highly purified CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 cells; cul-
tures were treated for periods of 4 to 15 d and then har-
vested for intravenous transplantation into NOD/SCID
mice. The BM of transplanted animals was analyzed 8 wk
after transplant by flow cytometry and Southern blot analy-
sis to determine the presence or absence of human repop-
ulating cells. Wells were seeded with 500–2,500 CD34
 
1
 
CD38
 
2
 
Lin
 
2
 
 cells containing approximately two to three
Figure 2. Characterization of
soluble hJagged-1. (A) Analysis of
Jagged-1 by Coomassie blue–
stained SDS-PAGE (i) and West-
ern blot analysis of purified
hJagged-1 IgG1 chimera using sec-
ondary, goat anti–human IgG1 an-
tibody (ii). MW is expressed in ki-
lodaltons. (B) Specific binding of
hJagged-1–FLAG chimera by hu-
man hematopoietic Lin2 cells. Re-
sults are expressed as mean fluores-
cence intensity 6 SEM compared
with controls (n 5 5). *Significant
difference P , 0.05. * and ** are
significantly different from each
other,  P , 0.01. hJagged-1–FLAG
binding was competed by pretreatment of cells with hJagged-1 IgG1 chimera before treating with the FLAG-
tagged ligand and by addition of 10 mM EDTA in staining buffer.1369 Karanu et al. Brief Definitive Report
SCID-repopulating cells (SRCs), as demonstrated by initial
limiting dilution analysis of de novo (day 0) isolated
CD341CD382Lin2 cells (data not shown). A summary of
the frequency of chimeric NOD/SCID mice transplanted
with control treated or Jagged-1–treated wells is shown in
Fig. 4 A, i and ii. Wells initially seeded with 1,000–2,500
CD341CD382Lin2 cells and treated with hJagged-1 con-
sistently gave rise to a greater frequency of chimeric NOD/
SCID mice as compared with mice transplanted with con-
trol treated cells (n 5 89) (Fig. 4 A, i). To allow for a
greater probability of evaluating single SRCs, as few as
1,000–500 CD341CD382Lin2 cells were initially seeded at
day 0 and cultured in the presence or absence of hJagged-1.
In these experiments, nearly all human repopulating cells
detected were derived only from cultures containing
hJagged-1 (n 5 36; Fig. 4 A, ii). In addition, the mean level
of human engraftment (indicated with horizontal bars) was
found to be higher in mice transplanted with Jagged-1–
treated stem cells (Fig. 4 A, i and ii), suggesting that Jagged-1
treatment before transplantation is capable of enhancing
Figure 3. Functional in vitro analysis of primary human CD341CD382Lin2 cells cultured in serum-free conditions containing hJagged-1. Highly pu-
rified CD341CD382Lin2 cells were isolated (purity .99%, Fig. 1 B) and seeded in 96-well plates containing serum-free medium and hematopoietic cy-
tokines in the presence of 10 mg/ml of soluble hJagged-1 or control recombinant IgG1. Cells were harvested at the indicated times, counted, phenotyped,
and seeded into methylcellulose for progenitor cell assays. (A) The fold increase in total cell number relative to cells seeded on day 0. Cells from individual
wells were counted, and the mean fold increase in absolute cell number was determined. Mean values 6 SEM are shown. Viability of control treated and
hJagged-1–treated cells was consistently .97%, indicating that increases in cell number and culture expansion are due to proliferation as opposed to dif-
ferential survival (data not shown). (B) Changes in the total number of primitive CD341CD382 cells in culture. The total number of CD341CD382 cells
was calculated using the total cell count from each well, and the frequencies of CD341CD382 cells were determined by flow cytometry. The mean fre-
quencies of CD341CD382 cells are shown as a percentage below the treatment for each time point. (C) Effect of Jagged-1 on the total number of clono-
genic progenitors. At the times indicated, an aliquot of cells was plated in methylcellulose culture. Total number of CFU per well was determined from
the cell input number and number of colonies observed. Values shown are the mean 6 SEM (n 5 5). *Significant difference, P , 0.05.1370 Jagged-1 Regulates Human Blood Stem Cells
clonal proliferative capacity of human stem cells in vivo.
Based on these results, we suggest that hJagged-1, unlike
conventional hematopoietic factors, is capable of augment-
ing the functional capacity of human reconstituting cells.
To further address whether hJagged-1 was capable of ex-
panding human SRCs, purified cells were cultured for 12
and 15 d in the presence or absence of Jagged-1, and har-
vested cells were divided into four equal aliquots for trans-
plantation into four individual NOD/SCID mice. Using
both flow cytometry and a human-specific probe, a repre-
sentative Southern blot shown in Fig. 4 B illustrates that
treatment with Jagged-1 resulted in a greater frequency of
human chimeric mice compared with animals transplanted
with control treated cultures (Fig. 4 B). To evaluate the in
vivo pluripotent capacity of human repopulating cells
treated with hJagged-1, mice transplanted with hJagged-1–
treated SRCs were analyzed by flow cytometric analysis.
Similar to control treated repopulating cells, mice trans-
planted with hJagged-1–treated stem cells contained hu-
man cells of multiple lineages, consisting of both lymphoid
and myeloid cells, and primitive CD341 cells (Fig. 4 C).
This analysis reveals that hJagged-1 is capable of acting on
human stem cells with pluripotent reconstituting ability,
without altering the developmental program or lineage de-
termination of the stem cell in vivo. As greater number of
mice were engrafted with hJagged-1–treated cells com-
pared with cells cultured in the presence of control cyto-
kines, we suggest that hJagged-1 is capable of enhancing
Figure 4. Analysis of engraft-
ment in NOD/SCID mice with
CD341CD382Lin2 cells cul-
tured in the absence or presence
hJagged-1. (A) Summary of levels
of human cell engraftment in the
BM of NOD/SCID mice trans-
planted with CD341CD382Lin2
cells cultured in the absence (s)
or presence (d) of Jagged-1 (10
mg/ml). Cells were cultured for
the different periods indicated
and transplanted by tail vein in-
jection into NOD/SCID recipi-
ents. (i) Mice injected with
1,000–2,500 CD341CD382Lin2
cells seeded on Day 0. (ii) Mice
injected with 500–1,000 cells
seeded on day 0. At days 12 and
15, horizontal bars indicate aver-
age level of human chimerism
achieved in engrafted mice. (B)
Representative Southern blot
analysis of individual NOD/
SCID mice transplanted with
four equally divided aliquots of
2,500 CD341CD382 cells seeded
at day 0 and cultured under se-
rum-free conditions for either 12
or 15 d in the presence or ab-
sence of hJagged-1. DNA was
extracted from recipient murine
BM 8 wk after the transplanta-
tion, separated on agarose gels,
and hybridized with the human
chromosome 17–specific a satel-
lite probe. The level of engraft-
ment was determined from the
human/mouse DNA controls
shown. (C) Multilineage differ-
entiation of human repopulating
cells in NOD/SCID mice after
ex vivo culture with or without
Jagged-1. Cells obtained from the
BM of engrafted mice were
stained with human specific
mAbs and analyzed by flow cy-
tometry. (i) Forward and side
scatter properties were used to gate live cells in R1 for analysis. (ii) Isotype control for nonspecific IgG1 staining for PE and FITC fluorescence. Human
cells (positive for panleukocyte marker CD45) were gated and analyzed for expression of the following human markers: (iii) pan-B cell markers for cells of
the lymphoid lineage CD19 and CD20, (iv) myeloid markers CD15 and CD33, and (v) CD38 and primitive cell markers CD34. Results are shown for
representative mice transplanted with control treated and Jagged-1–treated cultures.1371 Karanu et al. Brief Definitive Report
the survival and expansion of human reconstituting stem
cells. Therefore, unlike previously identified cytokines, our
data illustrates that although hJagged-1 has modest effects in
modulating mature progenitors detected in vitro (Fig. 3),
this ligand represents a novel hematopoietic growth factor
capable of expanding human blood cells with in vivo pluri-
potent reconstituting ability.
Discussion
Due to limitations in harvesting hematopoietic stem cells
used for transplantation and the requirement for stem cell
self-renewal for retroviral gene transfer in vitro, ex vivo ex-
pansion of human hematopoietic cells is a major focus of
clinical procedures (5). However, conditions capable of ex-
panding reconstituting cells that do not induce differentia-
tion and loss of stem cell function have yet to be demon-
strated using single or combinatory cytokines (4, 5). The
cloning, expression, and purification of soluble hJagged-1
has enabled us to treat primary human blood stem cells and
define the effect of hJagged-1 for the first time. Although
Jagged-1 had little effect on mature progenitor prolifera-
tion, the use of a human–mouse xenotransplantation model
for human stem cell detection provides the first evidence
that addition of a single factor, hJagged-1, can maintain and
expand primitive hematopoietic cells capable of multilin-
eage reconstitution in vivo without loss of progenitors.
These results indicate that hJagged-1 is unique to any
known hematopoietic growth factor tested to date. In addi-
tion, as hematopoietic cells themselves, along with stromal
microenvironments, have been shown here to express
Jagged-1, our results propose a unique paradigm in which
stromal and both mature and primitive hematopoietic cells
communicate via multidirectional Jagged-1®Notch signal-
ing. The biological effect of hJagged-1 on primitive cells
capable of repopulating immunodeficient mice demon-
strates that soluble hJagged-1 is a novel hematopoietic stem
cell growth factor in the human.
Potential roles of Notch signaling have been indicated in
humans through identification of somatic mutations that
cause human disease (28). However, segregating Jagged-1
mutations related to highly variable patient haploinsuffi-
cient phenotypes, and absence of Jagged-1 expression in ef-
fected tissues suggests the role of Jagged-1 is questionable.
As it is unknown if mutations in the Notch receptor repre-
sent gain or loss of Notch signaling function or if Jagged-1
mutations are a direct cause of disease, genetic analysis has
been unable to fully define a role and/or necessity of
Notch–ligand interactions in humans (3). Therefore, as our
study reveals a novel role of Jagged-1 in human physiology,
we suggest that this system provides a manner in which to
characterize the biological role of the Notch signaling in
humans and suggests that additional functions of Jagged-1
may remain to be demonstrated. For example, transplanta-
tion of neural or muscle stem cells has been postulated to
have clinical utility in replacing missing cells or the activa-
tion of endogenous cells to regenerate new tissue (29, 30)
and may eventually revolutionize therapies for neurode-
generative diseases or muscular dystrophy. However, be-
fore the full potential of these rare stem cells can be real-
ized, factors that control their proliferation must be
identified to expand these cells before implantation. As tis-
sue-specific stem cells may share common embryonic pro-
grams in response to environmental stimuli, similar out-
comes using hJagged-1 may apply to these tissue-specific
stem cells. Based on our current findings, it will be impor-
tant to examine whether hJagged-1 is capable of acting as a
neurogenic or myogenic stem cell regulator.
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